Clinical trials: N-Acetylcysteine
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
Pulmonary Fibrosis
Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to determine whether NAC added to prednisone, and azathioprine has a better effect on lung function, radiology and clinical condition than placebo + prednisone in combination with azathioprine after 6…
- Trial name
- IFIGENIA (NCT00639496)
- Testing
- n-acetylcysteine
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 184 people
- Sponsor
- Zambon SpA
Early Memory Loss, Mild Cognitive Impairment
NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed CerefolinNAC® are invited to participate in surveys regarding their experiences with CerefolinNAC®.
- Conditions
- Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
- Trial name
- NCT01370954
- Testing
- CerefolinNAC®
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Ulcerative Colitis, Left-sided Ulcerative Colitis
Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis
This double-blind, randomized, comparator-controlled Phase II study is designed to establish the safety and efficacy of Zoenasa Rectal Gel compared to mesalamine enema in subjects with left-sided ulcerative colitis, as measured…
- Conditions
- Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
- Trial name
- NCT01586533
- Testing
- Zoenasa-1:4, Mesalamine Enema
- Where
- 45 sites in United States
- Volunteers
- 120 people
- Sponsor
- Altheus Therapeutics, Inc.
Relapse Remitting Multiple Sclerosis
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
This study evaluates the effect of the therapy combining GA and NAC on disease activity as reflected by MRI parameters while assessing tolerability and safety.
- Trial name
- NCT00203099
- Testing
- Glatiramer Acetate, N-Acetylcysteine
- Volunteers
- 18 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
COPD
Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.
The objective is to assess efficacy and safety of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily treatment besides standard/usual treatment, as compared with placebo once daily in patients with stable…
- Trial name
- NCT03388853
- Testing
- Acetylcysteine/Doxofylline
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 68 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Common Cold
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
Prospective, randomized, multinational, multicenter, double-blind trial in 2 parallel groups of patients
- Trial name
- NCT05070650
- Testing
- Acetylcysteine, Paracetamol, Phenylephrine
- Sponsor
- Sandoz
Acetaminophen Overdose
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
- Trial name
- NCT01118663
- Testing
- Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cumberland Pharmaceuticals
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd
Healthy
A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers
A clinical study to measure the Safety, Tolerability, and Pharmacokinetics of OP-101 After Subcutaneous Administration in Healthy Volunteers
- Trial name
- NCT04321980
- Testing
- OP-101
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Orpheris, Inc.
Ulcerative Colitis
Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis
This Phase I study will be a closely monitored trial of a small number of subjects to establish, preliminarily, the tolerability and safety of two ALTH12 enema formulations: ALTH12-1:4 and ALTH12-2:4.
- Trial name
- NCT01020708
- Testing
- mesalamine, ALTH12-1:4, ALTH12-2:4
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Altheus Therapeutics, Inc.
Paracetamol Overdose
PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Investigate the safety and tolerability of PP100-01 add-on treatment to the 12hr NAC treatment regime in patients treated for paracetamol/acetaminophen overdose (POD) when NAC treatment is initiated before 24hours post POD.
- Trial name
- POP (NCT03177395)
- Testing
- PP100-01 (calmangafodipir), Acetylcysteine
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Egetis Therapeutics AB (publ)
Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
N-acetylcysteine (NAC), known to have mucolytic and antioxidant effects, is widely used to treat respiratory diseases and manage post-surgery pulmonary complications.
- Conditions
- Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis, Chronic Rhinosinusitis
- Trial name
- NOTUS (NCT04131686)
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers
A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.
- Trial name
- NCT03500627
- Testing
- OP-101
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Orpheris, Inc.
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
no Condition
Bioequivalence Study of Two Different Formulations of N-acetyl-cysteine (NAC)
Study primary Objective: To evaluate the bioequivalent rate (Cmax) and extent (AUC0-t) of absorption of N-acetyl-cysteine 600 mg uncoated tablets vs.
- Trial name
- NCT02265224
- Testing
- N-acetylcysteine
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Infections, Respiratory Tract
A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution
This is an open-label, randomized, single-center, 2-period, 2-sequence, single-dose crossover design study in adult male and female healthy participants.
- Trial name
- NCT02688361
- Testing
- Fluimucil® 2% solution, Acetylcysteine 2% solution
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Tract Disorders
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers
This is a single and multiple dose, single centre, open-label, one-way, pharmacokinetics, safety and tolerability clinical trial of Phase I to be performed in Chinese healthy male and female volunteers.
- Trial name
- NCT03881163
- Testing
- N-acetylcysteine (NAC)
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Rhinosinusitis
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
The trial was conducted as a prospective, randomized, multinational, multicenter, double-blind study in 4 parallel groups of patients.
- Trial name
- NCT04123405
- Testing
- acetylcysteine
- Where
- 37 sites in Bulgaria, Germany and 2 more
- Volunteers
- 944 people
- Sponsor
- Sandoz